NCT03686124 2026-04-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT03025256 2026-04-02
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT07501117 2026-03-30
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Herlev Hospital
Phase 1 Not yet recruiting
NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
Phase 1 Active not recruiting
NCT05987332 2026-02-17
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDEAYA Biosciences
Phase 2/3 Active not recruiting
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed